Pulse Biosciences (NASDAQ:PLSE) Price Target Raised to $74.00

Pulse Biosciences (NASDAQ:PLSE – Free Report) had its target price boosted by Canaccord Genuity Group from $58.00 to $74.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

PLSE has been the subject of a number of other research reports. Needham & Company LLC lifted their price target on Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a research note on Wednesday, September 9th. Oppenheimer raised their price objective on Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, October 13th. Finally, BTIG Research began coverage on Pulse Biosciences in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $66.60.

View Our Latest Stock Report on PLSE

Pulse Biosciences Stock Performance

Pulse Biosciences stock opened at $53.29 on Friday. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $58.90. The company has a fifty day simple moving average of $51.55 and a 200 day simple moving average of $32.28. The company has a market cap of $3.92 billion, a P/E ratio of -44.04 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Pulse Biosciences had a negative return on equity of 101.91% and a negative net margin of 5,603.88%. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.52 million. During the same quarter in the previous year, the company posted ($0.29) EPS. The business’s revenue was down 54.1% on a year-over-year basis. On average, equities research analysts forecast that Pulse Biosciences will post -1.34 EPS for the current year.

Insiders Place Their Bets

In related news, COO Liane Teplitsky bought 1,036 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the transaction, the chief operating officer owned 1,036 shares in the company, valued at $49,966.28. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders acquired 4,095 shares of company stock valued at $199,931. 74.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of large investors have recently bought and sold shares of PLSE. Osterweis Capital Management Inc. bought a new position in Pulse Biosciences in the second quarter valued at about $28,000. Sterling Capital Management LLC increased its stake in shares of Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock valued at $31,000 after buying an additional 549 shares during the period. Jupiter Topco LLC acquired a new position in shares of Pulse Biosciences in the second quarter valued at approximately $241,000. Axxcess Wealth Management LLC bought a new position in Pulse Biosciences in the 3rd quarter valued at approximately $242,000. Finally, GSA Capital Partners LLP bought a new position in Pulse Biosciences in the 2nd quarter valued at approximately $290,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Key Pulse Biosciences News

Here are the key news stories impacting Pulse Biosciences this week:

About Pulse Biosciences

(Get Free Report)

See Also

Analyst Recommendations for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.